Anteris Technologies Ltd is a publicly listed company on the Australian Securities Exchange under the ASX code AVR
Investor Centre
Investor News
Why Invest?
The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have
The Right Opportunity
to introduce a potential functional cure in the treatment of Aortic Stenosis where hemodynamics are reverted to normal pre-disease status and sustained for the life of the patient.
With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is
The Right Time
for a solution that Works Better & Lasts Longer.
At Anteris we bring
The Right Technology
to patients requiring a replacement valve. DurAVR™ heart valves address both the acute need in terms of superior hemodynamic profile, as well as chronic needs in their ability to sustain that profile longer, over the lifetime of the patient.The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.
The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to
potentially deliver a functional cure
in the treatment of Aortic Stenosis, and provides a much-needed solution to the challenges facing heart surgeons today.At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.
ASX Announcements
Subscribe to the ASX Annoucements Feed
Financial Reports
2021
- 2021 Consolidated Half Year Financial ReportView
Research Reports
- 2021 Consolidated Half Year Financial ReportView
- MST Access - AVR Update Report - Aug 21View
- MST Access - AVR Update Report - May 21View
- MST Access - Q4 Results: Fresh Funds Available, Trials Progressing WellView
- Bioshares November 2020 ReportView
- MST Access - Initiation of Coverage October 2020View
- Bioshares July 2020 ReportView
- ABID June 2020 ReportView
- Bioshares June 2020 ReportView
- NDF Research - ADAPTing to market opportunitiesView
Annual General Meetings
14th May 2020
Admedus AGM - May 202016th May 2019
Admedus AGM - May 201923rd May 2018
Admedus AGM - May 20181
Share Registry
Computershare Investor Services Pty Ltd
Level 1, 200 Mary Street
Brisbane, QLD 4000
T 1300 850 505 (within Australia)
T +61 3 9415 4000 (outside Australia)
F 1800 783 447 (within Australia)
F +61 3 9473 2555 (outside Australia)
ComputerShare Investor Services manages our share registry. You can contact them for details about your holding here.
A copy of our recent top 20 shareholder list is available here.